Patents by Inventor Hans Ulrich Stilz

Hans Ulrich Stilz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them
    Patent number: 6521654
    Abstract: Substituted imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: February 18, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
  • Vitronectin receptor antagonists, their preparation and their use
    Publication number: 20030027807
    Abstract: The present invention relates to compounds of the formula I
    Type: Application
    Filed: May 13, 2002
    Publication date: February 6, 2003
    Applicant: Genentech, Inc. and Hoechst Aktiengesellschaft
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Hydantoin derivatives as inhibitors of leucocyte adhesion and as VLA-4 antagonists
    Patent number: 6514952
    Abstract: Compounds of the formula I in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I, and of pharmaceutical preparations which contain such compounds, for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell—cell or cell-matrix interactions play a part which are based on interactions of VLA-4 receptors with their ligands, for example of inflammatory processes, rheumatoid arthritis or allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: February 4, 2003
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans Ulrich Stilz, Volkmar Wehner, Christoph Huels, Dirk Seiffge
  • Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients
    Publication number: 20020183374
    Abstract: The present invention relates to hydantoins of formula I, 1
    Type: Application
    Filed: March 8, 2002
    Publication date: December 5, 2002
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Klaus Burger, Alexander Golubev, Sergej Ossipov
  • Vitronectin receptor antagonists, their preparation and their use
    Patent number: 6482821
    Abstract: Vitronectin receptor antagonists, their preparation and their use The present invention relates to compounds of the formula I, A—B—D—E—F—G   (I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: November 19, 2002
    Assignees: Hoechst Aktiengellschaft, Genentech, Inc.
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Karlheinz Scheunemann, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them
    Publication number: 20020143043
    Abstract: Substituted imidazolidine derivatives of the formula I, 1
    Type: Application
    Filed: September 14, 2001
    Publication date: October 3, 2002
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
  • Tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them
    Patent number: 6459001
    Abstract: The subject of the invention is the products of formula (I): in which R1, R2, R3, R4, R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genetech
    Inventors: Serge Bernard, Denis Carniato, Jean-Francois Gourvest, Jean-Georges Teutsch, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Sarah C. Bodary, Thomas R. Gadek, Robert S. McDowell, Robert M. Pitti
  • Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
    Publication number: 20020119999
    Abstract: The present invention relates to 5-membered ring heterocycles of the formula I, 1
    Type: Application
    Filed: February 21, 2002
    Publication date: August 29, 2002
    Applicant: HOECHST AKTIENGESELLSCHAFT
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Denis Carniato, Jean-Francois Gourvest, Tom Gadek, Robert McDowell
  • 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
    Patent number: 6423712
    Abstract: The present invention relates to imidazolidine compounds of the formula I, The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: July 23, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
  • Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom
    Patent number: 6399643
    Abstract: The present invention relates to spiroimidazolidine derivatives of the formula I in which E, V, W, X, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, such as, for example, rheumatoid arthritis, or allergic disorders. The compounds of the formula I are also inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: June 4, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
  • Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists
    Patent number: 6399620
    Abstract: There are described cycloalkyl derivatives of the formula (I) R1—Y—A—B—D—E—F—G  (I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: June 4, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek, Robert McDowell, Robert Maurice Pitti, Sarah Catherine Bodary
  • Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
    Publication number: 20020065391
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: November 29, 2001
    Publication date: May 30, 2002
    Inventors: Hans Ulrich Stilz, Volkmar Wehner, Christoph Huls, Dirk Seiffge
  • Vitronectin receptor antagonists, their preparation and their use
    Patent number: 6387895
    Abstract: The present invention relates to compounds of the formula I A—B—D—E—F—G  (I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: May 14, 2002
    Assignees: Hoechst Aktiengesellschaft, Genentech, Inc.
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
    Patent number: 6365572
    Abstract: Low molecular weight peptide derivatives which are able to act as inhibitors of the interaction between laminin and nidogen (laminin/nidogen interaction), a process for their preparation, pharmaceutical compositions prepared therefrom and their use for preparing pharmaceuticals and for identifying inhibitors of the laminin/nidogen interaction.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: April 2, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hans Ulrich Stilz, Martin Gerl, Gary A. Flynn, Magda Stankova, Robert A. Binnie
  • Substituted benzimidazoles
    Patent number: 6358978
    Abstract: Compounds of formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF&kgr;B is involved.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: March 19, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, William Jerome Bock, Jr., Armin Walser, Gary A. Flynn, Jörg Habermann, Gerhard Jähne
  • Agents for promoting bone formation
    Patent number: 6344439
    Abstract: The object is to provide a promoting agent for bone formation, a therapeutic method for bone formation and a process for preparing a promoting agent for bone formation. A promoting agent for bone formation which comprises at least one of kistrin, echstatin, a peptide or polypeptide containing the amino acid sequence ArgGlyAsp in the molecule such as a peptide represented by Gly-Arg-Gly-Asp-Ser or a compound represented by the following general formula (IX) and so on, as well as a biologically acceptable salt thereof wherein R16 represents —N(R20)2 (R20 represents a hydrogen atom or a C1-C4 alkyl group), R17 represents a hydrogen atom or a C1-C4 alkyl group, R18 represents a hydrogen atom, a C1-C4 alkyl group and so on, R19 represents OH, NH2 and so on, Y represents —NH—, —O— or a direct bond, a represents 1-3, b represents 1 or 2, c represents 0 or 1 and d represents 0 or 1.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: February 5, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Kazuyuki Kitamura, Osamu Komiyama, Mizuho Inazu, Roland Baron, Thomas R. Gadek, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Robert S. McDowell
  • Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them
    Patent number: 6331552
    Abstract: Substituted imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: December 18, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
  • Salts of ethyl 3-(2-(4-(4-amino-imino-methyl)phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)acetylamino)-3-phenylpropionate
    Patent number: 6294562
    Abstract: The present invention relates to ethyl 3-(2-(4-(4-(amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate salts of the formula I, in which HM is maleic acid, and to their physiologically tolerated salts, thereof, to processes for their preparation and to their use in pharmaceuticals.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: September 25, 2001
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans Ulrich Stilz, Gerhard Beck, Manfred Radau
  • Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
    Publication number: 20010021708
    Abstract: The present invention relates to 5-membered ring heterocycles of the formula I, 1
    Type: Application
    Filed: March 6, 2001
    Publication date: September 13, 2001
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Denis Carniato, Jean-Francois Gourvest, Tom Gadek, Robert McDowell
  • Vitronectin receptor antagonists, their preparation and their use
    Publication number: 20010011087
    Abstract: Vitronectin receptor antagonists, their preparation and their use The present invention relates to compounds of the formula 1,
    Type: Application
    Filed: February 8, 2001
    Publication date: August 2, 2001
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Karlheinz Scheunemann, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell